<DOC>
	<DOCNO>NCT00559754</DOCNO>
	<brief_summary>This single arm study ass efficacy safety combination Avastin docetaxel follow cyclophosphamide doxorubicin , patient HER2 negative operable breast cancer . Patients receive 4 x 3 week cycle chemotherapy doxorubicin ( 60mg/m2 iv day 1 cycle ) cyclophosphamide ( 600mg/m2 iv day 1 cycle ) . They receive 4 x 3 week cycle docetaxel ( 75mg/m2 day 1 cycle ) combination Avastin ( 15mg/kg day 1 cycle ) . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Sequential Chemotherapy Patients With Primary HER2 Negative Operable Breast Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>female patient , &gt; =18 year age ; primary HER2negative operable breast cancer ; tumor &gt; 2cm size ; ECOG performance status 01. previous treatment breast cancer ; metastatic disease ; current recent ( within 10 day first dose Avastin ) use aspirin ( &gt; 325mg/day ) fulldose anticoagulant therapeutic purpose ; clinically significant cardiovascular disease .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>